The WCO-IOF-ESCEO 2026 meeting is only open to healthcare professionals who are registered for the congress. UCB medicines will be discussed at this event. UCB is a Platinum Sponsor of WCO-IOF-ESCEO 2026.
In the EU and the UK, EVENITY® is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.1,2 Licenses may vary by country. Please always refer to the Prescribing Information in your country before prescribing any drug. Adverse events should be reported. Reporting forms and information can be obtained from your local regulatory authority. For UK healthcare professionals, reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to UCB.
EVENITY (romosozumab) EU SmPC
EVENITY (romosozumab) UK Prescribing Information
Abbreviation: SmPC, Summary of Product Characteristics.
References: 1. EVENITY® (romosozumab) EU SmPC. https://www.ema.europa.eu/en/documents/product-information/evenity-epar-product-information_en.pdf. Accessed February 2026. 2. EVENITY® (romosozumab) UK SmPC. https://www.emcpi.com/pi/37322. Accessed February 2026.
© UCB Biopharma SRL, 2026. All rights reserved. Privacy Policy. GL-RM-2600005 | Date of preparation: February 2026
